Oral Hexadecyloxypropyl-Cidofovir Therapy in Pregnant Guinea Pigs Improves Outcome in the Congenital Model of Cytomegalovirus Infection
- 1 January 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (1), 35-41
- https://doi.org/10.1128/aac.00971-10
Abstract
Cytomegalovirus (CMV) infection is the leading cause of congenital infection, producing both sensorineural hearing loss and mental retardation. We evaluated the in vivo efficacy of an orally bioavailable analog of cidofovir, hexadecyloxypropyl-cidofovir (HDP-CDV), against guinea pig CMV (GPCMV) in a guinea pig model of congenital CMV infection. HDP-CDV exhibited antiviral activity against GPCMV with a 50% effective concentration (EC 50 ) of 0.004 μM ± 0.001 μM. To evaluate in vivo efficacy, pregnant Hartley guinea pigs were inoculated with GPCMV during the late second/early third trimester of gestation. Animals were administered 20 mg HDP-CDV/kg body weight orally at 24 h postinfection (hpi) and again at 7 days postinfection (dpi) or administered 4 mg/kg HDP-CDV orally each day for 5 days or 9 days. Virus levels in dam and pup tissues were evaluated following delivery, or levels from dam, placenta, and fetal tissues were evaluated following sacrifice of dams at 10 dpi. All HDP-CDV regimens significantly improved pup survival, from 50 to 60% in control animals to 93 to 100% in treated animals ( P ≤ 0.019). Treatment with 20 mg/kg HDP-CDV significantly reduced the viral load in pup spleen ( P = 0.017) and liver ( P = 0.029). Virus levels in the placenta were significantly reduced at 10 dpi following daily treatment with 4 mg/kg HDP-CDV for 5 or 9 days. The 9-day treatment also significantly reduced the viral levels in the dam spleen and liver. Although the 4-mg/kg treatment improved pup survival, virus levels in the fetal tissues were similar to those in control tissues. Taken together, HDP-CDV shows potential as a well-tolerated antiviral candidate for treatment of congenital human CMV (HCMV) infection.This publication has 48 references indexed in Scilit:
- Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous systemJournal of Clinical Virology, 2009
- Antivirals for Cytomegalovirus Infection in Neonates and InfantsPediatric Drugs, 2009
- Vaccine Prevention of Maternal Cytomegalovirus InfectionThe New England Journal of Medicine, 2009
- Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategiesJournal of Antimicrobial Chemotherapy, 2009
- Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapiesVirology, 2009
- Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelProceedings of the National Academy of Sciences of the United States of America, 2008
- Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus DiseaseThe Journal of Infectious Diseases, 2008
- Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infantJournal of Perinatology, 2007
- Synergistic Efficacy of the Combination of ST-246 with CMX001 against OrthopoxvirusesAntimicrobial Agents and Chemotherapy, 2007
- Placental cytomegalovirus infection withoutfetal involvement following primary infection in pregnancyThe Journal of Pediatrics, 1971